The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood–brain barrier in vitro

Brain Research

Volumn 1648, Issue , 2016, Pages 232-242

  Watson, Christopher P ^a   Pazarentzos, Evangelos ^b   Fidanboylu, Mehmet ^a   Padilla, Beatriz ^a   Brown, Rachel ^a   Thomas, Sarah A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cationic amino acid transporter 1; Cerebral microvasculature; Guanosine triphosphatases (GTPases); Nitric oxide

Indexed keywords

AMINO ACID TRANSPORTER; ARGININE; DDAH 1 ENZYME; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GAMMA INTERFERON; HYDROLASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; OXYGENASE INHIBITOR; SUCROSE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ENZYME INHIBITOR; N(G)-IMINOETHYLORNITHINE; N,N-DIMETHYLARGININE; ORNITHINE; REACTIVE OXYGEN METABOLITE; SLC7A1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CELL VIABILITY; CHEMICAL INTERACTION; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MTT ASSAY; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PERMEABILITY;

ARGININE; BLOOD-BRAIN BARRIER; CATIONIC AMINO ACID TRANSPORTER 1; CELL LINE; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; IN VITRO TECHNIQUES; INTERFERON-GAMMA; NITRIC OXIDE; ORNITHINE; PERMEABILITY; REACTIVE OXYGEN SPECIES; SUCROSE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84982803376     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2016.07.026     Document Type: Article

References (80)

1. Abdelmagid, S.A., Rickard, J.A., Mcdonald, W.J., Thomas, L.N., Too, C.K., CAT- 1-mediated arginine uptake and regulation of nitric oxide synthases for the survival of human breast cancer cell lines. J. Cell. Biochem. 112 (2011), 1084–1092.
2. Abbott, N.J., Ronnback, L., Hansson, E., Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7 (2006), 41–53.
3. Arlt, S., Schulze, F., Eichenlaub, M., Maas, R., Lehmbeck, J.T., Schwedhelm, E., Jahn, H., Boger, R.H., Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 26 (2008), 58–64.
4. Battisti, S., Valente, D., Albonici, L., Bei, R., Modesti, A., Palumbo, C., Nutritional stress and arginine auxotrophy confer high sensitivity to chloroquine toxicity in mesothelioma cells. Am. J. Respir. Cell Mol. Biol. 46 (2012), 498–506.
5. Boger, R.H., The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc. Res. 59 (2003), 824–833.
6. Boger, R.H., Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J. Nutr. 134 (2004), 2842S–2847S discussion 2853S.
7. Boger, R.H., Bode-Boger, S.M., Szuba, A., Tsao, P.S., Chan, J.R., Tangphao, O., Blaschke, T.F., Cooke, J.P., Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998), 1842–1847.
8. Brouns, R., Marescau, B., Possemiers, I., Sheorajpanday, R., De Deyn, P.P., Dimethylarginine levels in cerebrospinal fluid of hyperacute ischemic stroke patients are associated with stroke severity. Neurochem. Res. 34 (2009), 1642–1649.
9. Carl, S.M., Lindley, D.J., Couraud, P.O., Weksler, B.B., Romero, I., Mowery, S.A., Knipp, G.T., ABC and SLC transporter expression and pot substrate characterization across the human CMEC/D3 blood-brain barrier cell line. Mol. Pharm. 7 (2010), 1057–1068.
10. Cecchelli, R., Dehouck, B., Descamps, L., Fenart, L., Buee-Scherrer, V.V., Duhem, C., Lundquist, S., Rentfel, M., Torpier, G., Dehouck, M.P., In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 36 (1999), 165–178.
11. Chen, Y., Xu, X., Sheng, M., Zhang, X., Gu, Q., Zheng, Z., PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy. Exp. Eye Res. 89 (2009), 1028–1034.
12. Chen, Y.H., Xu, X., Sheng, M.J., Zheng, Z., Gu, Q., Effects of asymmetric dimethylarginine on bovine retinal capillary endothelial cell proliferation, reactive oxygen species production, permeability, intercellular adhesion molecule-1, and occludin expression. Mol. Vis. 17 (2011), 332–340.
13. Chrissobolis, S., Miller, A.A., Drummond, G.R., Kemp-Harper, B.K., Sobey, C.G., Oxidative stress and endothelial dysfunction in cerebrovascular disease. Front. Biosci. 16 (2011), 1733–1745.
14. Closs, E.I., Simon, A., Vekony, N., Rotmann, A., Plasma membrane transporters for arginine. J. Nutr. 134 (2004), 2752S–2759S discussion 2853S.
15. D'agostino, D.P., Putnam, R.W., Dean, J.B., Superoxide (*O2–) production in CA1 neurons of rat hippocampal slices exposed to graded levels of oxygen. J. Neurophysiol. 98 (2007), 1030–1041.
16. Dayoub, H., Rodionov, R.N., Lynch, C., Cooke, J.P., Arning, E., Bottiglieri, T., Lentz, S.R., Faraci, F.M., Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke 39 (2008), 180–184.
17. Dehouck, M.P., Jolliet-Riant, P., Bree, F., Fruchart, J.C., Cecchelli, R., Tillement, J.P., Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J. Neurochem. 58 (1992), 1790–1797.
18. Dejana, E., Orsenigo, F., Lampugnani, M.G., The role of adherens junctions and VE-cadherin in the control of vascular permeability. J. Cell Sci. 121 (2008), 2115–2122.
19. Diaz-Perez, F., Radojkovic, C., Aguilera, V., Veas, C., Gonzalex, M., Lamperti, L., Escudero, C., Aguayo, C., L-Arginine transport and nitric oxide synthesis in human endothelial progenitor cells. J. Cardiovasc. Pharm. 60 (2012), 439–449.
20. Fletcher, N.F., Wilson, G.K., Murray, J., Hu, K., Lewis, A., Reynolds, G.M., Stamataki, Z., Meredith, L.W., Rowe, I.A., Luo, G., Lopez-Ramirez, M.A., Baumert, T.F., Weksler, B., Couraud, P.O., Kim, K.S., Romero, I.A., Jopling, C., Morgello, S., Balfe, P., Mckeating, J.A., Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology, 2011.
21. Forster, C., Burek, M., Romero, I.A., Weksler, B., Couraud, P.O., Drenckhahn, D., Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J. Physiol. 586 (2008), 1937–1949.
22. Hoffmann, A., Bredno, J., Wendland, M., Derugin, N., Ohara, P., Wintermark, M., High and low molecular weight fluorescein isothiocyanate (FITC)-dextrans to assess blood-brain barrier disruption: technical considerations. Transl. Stroke Res. 2 (2011), 106–111.
23. Jeganathan, S., Sanderson, L., Dogruel, M., Rodgers, J., Croft, S., Thomas, S.A., The distribution of nifurtimox across the healthy and trypanosome-infected murine blood-brain and blood-CSF barriers. J. Pharm. Exp. Ther. 336 (2011), 506–515.
24. Kielstein, J.T., Donnerstag, F., Gasper, S., Menne, J., Kielstein, A., Martens-Lobenhoffer, J., Scalera, F., Cooke, J.P., Fliser, D., Bode-Boger, S.M., ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37 (2006), 2024–2029.
25. Kielstein, J.T., Kielstein, A., ADMA and the brain: an unfolding story. Am. J. Hypertens., 22, 2009, 240.
26. Kittel, A., Maas, R., Pharmacology and clinical pharmacology of methylarginines used as inhibitors of nitric oxide synthases. Curr. Pharm. Des. 20 (2014), 3530–3547.
27. Laskowska, M., Laskowska, K., Oleszczuk, J., The relation of maternal serum eNOS, NOSTRIN and ADMA levels with aetiopathogenesis of preeclampsia and/or intrauterine fetal growth restriction. J. Matern. Fetal Neonatal. Med., 2014.
28. Leiper, J., Nandi, M., Torondel, B., Murray-Rust, J., Malaki, M., O'hara, B., Rossiter, S., Anthony, S., Madhani, M., Selwood, D., Smith, C., Wojciak-Stothard, B., Rudiger, A., Stidwill, R., Mcdonald, N.Q., Vallance, P., Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med. 13 (2007), 198–203.
29. Leiper, J., Vallance, P., Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 43 (1999), 542–548.
30. Lin, K.Y., Ito, A., Asagami, T., Tsao, P.S., Adimoolam, S., Kimoto, M., Tsuji, H., Reaven, G.M., Cooke, J.P., Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002), 987–992.
31. Lundman, P., Eriksson, M.J., Stuhlinger, M., Cooke, J.P., Hamsten, A., Tornvall, P., Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J. Am. Coll. Cardiol. 38 (2001), 111–116.
32. Mcdonald, K.K., Zharikov, S., Block, E.R., Kilberg, M.S., A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the “arginine paradox”. J. Biol. Chem. 272 (1997), 31213–31216.
33. Minagar, A., Alexander, J.S., Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9 (2003), 540–549.
34. Moller, P., Alvestrand, A., Bergstrom, J., Furst, P., Hellstrom, K., Electrolytes and free amino acids in leg skeletal muscle of young and elderly women. Gerontology 29 (1983), 1–8.
35. Moller, P., Bergstrom, J., Eriksson, S., Furst, P., Hellstrom, K., Effect of aging on free amino acids and electrolytes in leg skeletal muscle. Clin. Sci. 56 (1979), 427–432.
36. Mun, G.I., Kim, I.-S., Lee, B.-Y., Boo, Y.C., Endothelial argininosuccinate synthetase 1 regulates nitric oxide production and monocyte adhesion under static and laminar shear stress conditions. J. Biol. Chem. 286 (2011), 2536–2542.
37. Murakami, H., Murakami, R., Kambe, F., Cao, X., Takahashi, R., Asai, T., Hirai, T., Numaguchi, Y., Okumura, K., Seo, H., Murohara, T., Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem. Biophys. Res. Commun. 341 (2006), 973–978.
38. Notsu, Y., Nabika, T., Bokura, H., Suyama, Y., Kobayashi, S., Yamaguchi, S., Masuda, J., Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am. J. Hypertens. 22 (2009), 257–262.
39. Ohtsuki, S., Ikeda, C., Uchida, Y., Sakamoto, Y., Miller, F., Glacial, F., Decleves, X., Scherrmann, J.M., Couraud, P.O., Tachikawa, M., Terasaki, T., Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol. Pharm. 10 (2013), 289–296.
40. O'kane, R.L., Vina, J.R., Simpson, I., Zaragoza, R., Mokashi, A., Hawkins, R.A., Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+. Am. J. Physiol. Endocrinol. Metab. 291 (2006), E412–E419.
41. Palm, F., Onozato, M.L., Luo, Z., Wilcox, C.S., Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am. J. Physiol. Heart Circ. Physiol. 293 (2007), H3227–H3245.
42. Patabendige, A., Skinner, R.A., Abbott, N.J., Establishment of a simplified in vitro porcine blood-brain barrier model with high transendothelial electrical resistance. Brain Res., 2012.
43. Perticone, F., Sciacqua, A., Maio, R., Perticone, M., Maas, R., Boger, R.H., Tripepi, G., Sesti, G., Zoccali, C., Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J. Am. Coll. Cardiol. 46 (2005), 518–523.
44. Poller, B., Gutmann, H., Krahenbuhl, S., Weksler, B., Romero, I., Couraud, P.O., Tuffin, G., Drewe, J., Huwyler, J., The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J. Neurochem. 107 (2008), 1358–1368.
45. Psychogios, N., hau, D.D., Peng, J., Guo, A.C., Mandal, R., Bouatra, S., Sinelnikov, I., Krishnamurthy, R., Eisner, R., Gautam, B., Young, N., Xia, J., Knox, C., Dong, E., Huang, P., Hollander, Z., Pedersen, T.L., Smith, S.R., Bamforth, F., Greiner, R., Mcmanus, B., Newman, J.W., Goodfriend, T., Wishart, D.S., The human serum metabolome. PLoS One, 6, 2011, e16957.
46. Rees, D.D., Palmer, R.M., Schulz, R., Hodson, H.F., Moncada, S., Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharm. 101 (1990), 746–752.
47. Rotmann, A., Simon, A., Martine, U., Habermeier, A., Closs, E.I., Activation of classical protein kinase C decreases transport via systems y+ and y+L. Am. J. Physiol. Cell. Physiol. 292 (2007), C2259–C2268.
48. Sanderson, L., Dogruel, M., Rodgers, J., Bradley, B., Thomas, S.A., The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. J. Neurochem. 107 (2008), 1136–1146.
49. Sandoval, K.E., Witt, K.A., Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol. Dis. 32 (2008), 200–219.
50. Scherbakov, N., Sandek, A., Martens-Lobenhoffer, J., Kung, T., Turhan, G., Liman, T., Ebinger, M., V.O.N. Haehling, S., Bode-Boger, S.M., Endres, M., Doehner, W., Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke. Cereb. Dis. 33 (2012), 37–46.
51. Selley, M.L., Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol. Aging 24 (2003), 903–907.
52. Siroen, M.P., Teerlink, T., Nijveldt, R.J., Prins, H.A., Richir, M.C., Leeuwen, P. A, V.A.N., The clinical significance of asymmetric dimethylarginine. Annu. Rev. Nutr. 26 (2006), 203–228.
53. Spindler, V., Schlegel, N., Waschke, J., Role of GTPases in control of microvascular permeability. Cardiovasc. Res. 87 (2010), 243–253.
54. Strobel, J., Mieth, M., Endress, B., Auge, D., Konig, J., Fromm, M.F., Maas, R., Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). J. Mol. Cell. Cardiol. 53 (2012), 392–400.
55. Strobel, J., Muller, F., Zolk, O., Endress, B., Konig, J., Fromm, M.F., Maas, R., Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1). Amino Acids 45 (2013), 989–1002.
56. Stupack, D.G., Cheresh, D.A., Apoptotic cues from the extracellular matrix: Regulators of angiogenesis. Oncogene 22 (2003), 9022–9029.
57. Sydow, K., Munzel, T., ADMA and oxidative stress. Atheroscler. Suppl. 4 (2003), 41–51.
58. Sydow, K., Schwedhelm, E., Arakawa, N., Bode-Boger, S.M., Tsikas, D., Hornig, B., Frolich, J.C., Boger, R.H., ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc. Res. 57 (2003), 244–252.
59. Tai, L.M., Reddy, P.S., Lopez-Ramirez, M.A., Davies, H.A., Male, D.K., Loughlin, A.J., Romero, I.A., Polarized P-glycoprotein expression by the immortalised human brain endothelial cell line, hCMEC/D3, restricts apical-to-basolateral permeability to rhodamine 123. Brain Res. 1292 (2009), 14–24.
60. Tain, Y.L., Baylis, C., Determination of dimethylarginine dimethylaminohydrolase activity in the kidney. Kidney Int. 72 (2007), 886–889.
61. Teerlink, T., Luo, Z., Palm, F., Wilcox, C.S., Cellular ADMA: regulation and action. Pharm. Res. 60 (2009), 448–460.
62. Thiel, V.E., Audus, K.L., Nitric oxide and blood-brain barrier integrity. Antioxid. Redox Signal. 3 (2001), 273–278.
63. Tran, C.T., Leiper, J.M., Vallance, P., The DDAH/ADMA/NOS pathway. Atheroscler. Suppl. 4 (2003), 33–40.
64. Tripathy, D., Yin, X., Sanchez, A., Luo, J., Martinez, J., Grammas, P., Cerebrovascular expression of proteins related to inflammation, oxidative stress and neurotoxicity is altered with aging. J. Neuroinflammation, 7, 2010, 63.
65. Uttara, B., Singh, A.V., Zamboni, P., Mahajan, R.T., Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7 (2009), 65–74.
66. Vallance, P., Leone, A., Calver, A., Collier, J., Moncada, S., Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharm. 20:Suppl 12 (1992), S60–S62.
67. Wanby, P., Teerlink, T., Brudin, L., Brattstrom, L., Nilsson, I., Palmqvist, P., Carlsson, M., Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 185 (2006), 271–277.
68. Wang, L.Y., Zhang, D.L., Zheng, J.F., Zhang, Y., Zhang, Q.D., Liu, W.H., Apelin-13 passes through the ADMA-damaged endothelial barrier and acts on vascular smooth muscle cells. Peptides 32 (2011), 2436–2443.
69. Watson, C.P., Dogruel, M., Mihoreanu, L., Begley, D.J., Weksler, B.B., Couraud, P.O., Romero, I.A., Thomas, S.A., The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein. Brain Res. 1436 (2012), 111–121.
70. Weksler, B.B., Subileau, E.A., Perriere, N., Charneau, P., Holloway, K., Leveque, M., Tricoire-Leignel, H., Nicotra, A., Bourdoulous, S., Turowski, P., Male, D.K., Roux, F., Greenwood, J., Romero, I.A., Couraud, P.O., Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19 (2005), 1872–1874.
71. Weksler, B.B., Romero, I.A., Couraud, P.O., The hCMEC/D3 cell line as a model of the human blood-brain barrier. Fluids Barriers CNS, 10, 2013, 16.
72. White, M.F., The transport of cationic amino acids across the plasma membrane of mammalian cells. Biochim. Biophys. Acta 822 (1985), 355–374.
73. Wojciak-Stothard, B., Torondel, B., Tsang, L.Y., Fleming, I., Fisslthaler, B., Leiper, J.M., Vallance, P., The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J. Cell Sci. 120 (2007), 929–942.
74. Wojciak-Stothard, B., Torondel, B., Zhao, L., Renne, T., Leiper, J.M., Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function. Mol. Biol. Cell 20 (2009), 33–42.
75. Xiao, S., Wagner, L., Mahaney, J., Baylis, C., Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am. J. Physiol. Ren. Physiol. 280 (2001), F989–F995.
76. Yamaoka, J., Kabashima, K., Kawanishi, M., Toda, K., Miyachi, Y., Cytotoxicity of IFN-gamma and TNF-alpha for vascular endothelial cell is mediated by nitric oxide. Biochem. Biophys. Res. Commun. 291 (2002), 780–786.
77. Yoo, J.H., Lee, S.C., Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 158 (2001), 425–430.
78. Zhang, P., Hu, X., Xu, X., Chen, Y., Bache, R., Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 890–897.
79. Zharikov, S.I., Sigova, A.A., Chen, S., Bubb, M.R., Block, E.R., Cytoskeletal regulation of the L-arginine/NO pathway in pulmonary artery endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 280 (2001), L465–L473.
80. Zougbede, S., Miller, F., Ravassard, P., Rebollo, A., Ciceron, L., Couraud, P.O., Mazier, D., Moreno, A., Metabolic acidosis induced by Plasmodium falciparum intraerythrocytic stages alters blood-brain barrier integrity. J. Cereb. Blood Flow Metab. 31 (2011), 514–526.